Literature DB >> 17630561

Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART.

Per Björkman1, Leo Flamholc, Vilma Molnegren, Aline Marshall, Nuray Güner, Anders Widell.   

Abstract

In patients co-infected with HIV-1 and GB virus C (GBV-C), the disappearance of GBV-C RNA has been associated with accelerated disease progression. We studied longitudinal GBV-C viral titres in 28 HIV-1/GVB-C co-infected individuals receiving HAART. During HAART, median GBV-C RNA titres increased from 95 to 6000 copies/ml (P < 0.001). In patients interrupting HAART, GBV-C-RNA titres decreased as HIV replication resumed. These findings further support the theory that GBV-C replication could depend on the dynamics of HIV progression.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17630561     DOI： 10.1097/QAD.0b013e32823bc9b7

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  15 in total

1.  Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients.

Authors:  Farnaz Vahidnia; M Petersen; G Rutherford; M Busch; S Assmann; J T Stapleton; B Custer
Journal:  J Infect Dis       Date:  2012-03-20       Impact factor: 5.226

2.  Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.

Authors:  Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

Review 3.  Role of GB virus C in modulating HIV disease.

Authors:  Carolynne Schwarze-Zander; Jason T Blackard; Juergen K Rockstroh
Journal:  Expert Rev Anti Infect Ther       Date:  2012-05       Impact factor: 5.091

4.  Downregulation of Cytokines and Chemokines by GB Virus C After Transmission Via Blood Transfusion in HIV-Positive Blood Recipients.

Authors:  Marion C Lanteri; Farnaz Vahidnia; Sylvia Tan; Jack T Stapleton; Philip J Norris; John Heitman; Xutao Deng; Sheila M Keating; Don Brambilla; Michael P Busch; Brian Custer
Journal:  J Infect Dis       Date:  2014-11-25       Impact factor: 5.226

5.  Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.

Authors:  James H McLinden; Jack T Stapleton; Donna Klinzman; Krishna K Murthy; Qing Chang; Thomas M Kaufman; Nirjal Bhattarai; Jinhua Xiang
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

6.  Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents.

Authors:  Solveig Tenckhoff; Thorsten Kaiser; Fritz Bredeek; Sharyne Donfield; Erika Menius; Alice Lail; Joachim Mössner; Eric S Daar; Hans L Tillmann
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

7.  GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy.

Authors:  Jack T Stapleton; Kathryn Chaloner; Jingyang Zhang; Donna Klinzman; Inara E Souza; Jinhua Xiang; Alan Landay; John Fahey; Richard Pollard; Ronald Mitsuyasu
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

8.  Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication.

Authors:  Jinhua Xiang; James H McLinden; Qing Chang; Emma L Jordan; Jack T Stapleton
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

9.  Virus against virus (VIVI): a potential solution against HIV/AIDS.

Authors:  Asfandyar Sheikh; Muhammad Farhan Khaliq; Muhammad Muslim Noorani
Journal:  Int Arch Med       Date:  2014-05-06

10.  GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals.

Authors:  Jack T Stapleton; Kathryn Chaloner; Jeffrey A Martenson; Jingyang Zhang; Donna Klinzman; Jinhua Xiang; Wendy Sauter; Seema N Desai; Alan Landay
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.